BR112021016865A2 - Composição para prevenção, melhora ou tratamento de obesidade ou doença hepática gordurosa compreendendo weissella hellenica wikim0103 - Google Patents

Composição para prevenção, melhora ou tratamento de obesidade ou doença hepática gordurosa compreendendo weissella hellenica wikim0103

Info

Publication number
BR112021016865A2
BR112021016865A2 BR112021016865A BR112021016865A BR112021016865A2 BR 112021016865 A2 BR112021016865 A2 BR 112021016865A2 BR 112021016865 A BR112021016865 A BR 112021016865A BR 112021016865 A BR112021016865 A BR 112021016865A BR 112021016865 A2 BR112021016865 A2 BR 112021016865A2
Authority
BR
Brazil
Prior art keywords
wikim0103
preventing
liver disease
fatty liver
composition
Prior art date
Application number
BR112021016865A
Other languages
English (en)
Inventor
CHOI Hak-Jong
LIM Seul-Ki
Original Assignee
Korea Food Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Food Res Inst filed Critical Korea Food Res Inst
Publication of BR112021016865A2 publication Critical patent/BR112021016865A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065—Microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/332—Promoters of weight control and weight loss
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Animal Husbandry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

composição para prevenção, melhora ou tratamento de obesidade ou doença hepática gordurosa compreendendo weissella hellenica wikim0103. refere-se a uma nova cepa weissella hellenica wikim0103 isolada de kimchi e a uma composição compreendendo a mesma ou seu uso. a presente invenção apresenta um método para prevenção, melhora e tratamento de inflamação, obesidade ou doença hepática gordurosa de um indivíduo, por meio da administração da nova cepa weissella hellenica wikim0103 isolada de kimchi ou uma composição contendo a mesma. a weissella hellenica wikim0103, de acordo com a presente invenção, mostra um efeito inibitório para a produção de esteatose hepática ao inibir o acúmulo de gordura nas células hepáticas e reduzir a expressão de genes relacionados à esteatose hepática e, portanto, pode ser utilizada de várias maneiras para usos na prevenção, na melhora e no tratamento de inflamação, obesidade ou doença hepática gordurosa.
BR112021016865A 2019-02-28 2020-02-27 Composição para prevenção, melhora ou tratamento de obesidade ou doença hepática gordurosa compreendendo weissella hellenica wikim0103 BR112021016865A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020190024255A KR102072059B1 (ko) 2019-02-28 2019-02-28 와이셀라 헬레니카 WiKim0103를 포함하는 비만 또는 지방간 질환의 예방, 개선 또는 치료용 조성물
PCT/KR2020/002844 WO2020175939A1 (ko) 2019-02-28 2020-02-27 와이셀라 헬레니카 wikim0103를 포함하는 비만 또는 지방간 질환의 예방, 개선 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
BR112021016865A2 true BR112021016865A2 (pt) 2021-11-23

Family

ID=69369321

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021016865A BR112021016865A2 (pt) 2019-02-28 2020-02-27 Composição para prevenção, melhora ou tratamento de obesidade ou doença hepática gordurosa compreendendo weissella hellenica wikim0103

Country Status (10)

Country Link
US (1) US20220160796A1 (pt)
EP (1) EP3933030A4 (pt)
JP (1) JP7266110B2 (pt)
KR (1) KR102072059B1 (pt)
CN (1) CN113508173A (pt)
AU (1) AU2020229728A1 (pt)
BR (1) BR112021016865A2 (pt)
CA (1) CA3131410A1 (pt)
MX (1) MX2021010349A (pt)
WO (1) WO2020175939A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102072059B1 (ko) * 2019-02-28 2020-01-31 한국식품연구원 와이셀라 헬레니카 WiKim0103를 포함하는 비만 또는 지방간 질환의 예방, 개선 또는 치료용 조성물
KR102328742B1 (ko) * 2020-06-12 2021-11-22 숙명여자대학교산학협력단 신규한 와이셀라 시바리아 균주 및 이의 유청 발효물을 포함하는 비만 또는 지방간 질환의 예방 또는 개선용 식품 조성물
WO2022139532A1 (ko) * 2020-12-23 2022-06-30 주식회사 리스큐어바이오사이언시스 와이셀라 헬레니카 유래 세포밖 소포체를 유효성분으로 포함하는 지방간 개선, 예방 또는 치료용 조성물
KR20220091429A (ko) 2020-12-23 2022-06-30 주식회사 리스큐어바이오사이언시스 와이셀라 헬레니카 유래 세포밖 소포체를 유효성분으로 포함하는 지방간 개선, 예방 또는 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100037310A (ko) * 2008-10-01 2010-04-09 주식회사 비티엠 김치 유산균을 이용한 액상 건강보조식품의 제조방법
KR101130695B1 (ko) * 2010-01-08 2012-04-02 우석대학교 산학협력단 오르니틴을 생산하는 능력이 있는 바이셀라 코리엔시스 ｏｋ1-6 균주, 상기 균주를 이용하여 오르니틴을 함유하는 김치의 제조방법 및 상기 방법에 의해 제조한 김치
KR20110134151A (ko) * 2010-06-08 2011-12-14 주식회사 케이씨아이 혼합 균 배양물을 포함하는 피부 염증질환 개선제, 이를 포함하는 화장료 조성물 및 약제학적 조성물
US9468657B2 (en) * 2010-06-08 2016-10-18 Asahi Group Holdings, Ltd. Lactic acid bacterium agent for improving lipid metabolism
US8906668B2 (en) * 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
KR20170000510A (ko) * 2015-06-24 2017-01-03 주식회사 대유위니아 항비만 유산균의 발생을 위한 김치의 숙성방법 및 이것이 프로그래밍된 냉장고
KR101750850B1 (ko) * 2015-09-08 2017-06-29 대한민국 바이셀라 코리엔시스의 특이적 프라이머 쌍 및 이를 이용한 바이셀라 코리엔시스의 검출방법
KR20170032815A (ko) 2015-09-15 2017-03-23 경희대학교 산학협력단 신규 유산균 및 퇴행성 뇌질환 또는 인지기능의 예방, 개선 또는 치료용 조성물
JP7358001B2 (ja) * 2018-02-16 2023-10-10 イチビキ株式会社 乳酸菌、インターロイキン－２２産生誘導剤、皮膚バリア機能増強剤
KR102072059B1 (ko) * 2019-02-28 2020-01-31 한국식품연구원 와이셀라 헬레니카 WiKim0103를 포함하는 비만 또는 지방간 질환의 예방, 개선 또는 치료용 조성물

Also Published As

Publication number Publication date
CN113508173A (zh) 2021-10-15
MX2021010349A (es) 2022-01-06
EP3933030A1 (en) 2022-01-05
EP3933030A4 (en) 2022-12-28
US20220160796A1 (en) 2022-05-26
AU2020229728A1 (en) 2021-09-30
WO2020175939A1 (ko) 2020-09-03
CA3131410A1 (en) 2020-09-03
JP7266110B2 (ja) 2023-04-27
KR102072059B1 (ko) 2020-01-31
JP2022522727A (ja) 2022-04-20

Similar Documents

Publication Publication Date Title
BR112021016879A2 (pt) Composição para prevenção, melhora ou tratamento de obesidade ou doença hepática gordurosa compreendendo leuconostoc citreum wikim0104
BR112021016865A2 (pt) Composição para prevenção, melhora ou tratamento de obesidade ou doença hepática gordurosa compreendendo weissella hellenica wikim0103
Sadaf et al. Arsenic trioxide induces apoptosis and inhibits the growth of human liver cancer cells
ECSP21075909A (es) Inhibidores de la proteína tirosina fosfatasa y métodos para usarlos
PE20211212A1 (es) AGENTES DE ARNi PARA INHIBIR LA EXPRESION DE 17beta-HSD TIPO 13 (HSD17B13), COMPOSICIONES DE DICHOS AGENTES, Y METODOS DE USO
DOP2018000182A (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo
CO2021000447A2 (es) Inhibidores de proteína tirosina fosfatasa y sus métodos de uso
BR112016029781A2 (pt) composições e métodos para inibir a expressão de gene de alfa-1 antitripsina
BR112017017178A2 (pt) moduladores específicos de alelo de rodopsina de p23h
CL2021001490A1 (es) Constructos de iarn modificados químicamente y usos de estos
Yang et al. Methanol extract of Hopea odorata suppresses inflammatory responses via the direct inhibition of multiple kinases
CL2023000371A1 (es) Composiciones y métodos para inhibir la expresión de plp1.
BR112022009409A2 (pt) Novos derivados que têm grupamento 2,3-dihidro-1h-indeno ou 2,3-dihidrobenzofurano ou sal farmaceuticamente aceitável dos mesmos e composições farmacêuticas que os compreendem
BR112021019262A2 (pt) Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose
BR112017020307A2 (pt) método para inibir os sintomas associados com a ingestão de álcool, e, composição farmacêutica
Manaharan et al. Antimetastatic and anti-inflammatory potentials of essential oil from edible Ocimum sanctum leaves
Valerio et al. β-Sitosterol modulates TLR4 receptor expression and intracellular MyD88-dependent pathway activation in J774A. 1 murine macrophages
BR112023001957A2 (pt) Composições e métodos para inibir expressão de lpa
BR112023017367A2 (pt) Composições e métodos para inibição de ceto-hexoquinase (khk)
Handayani et al. Brazilein in combination with cisplatin inhibit proliferation and migration on highly metastatic cancer cells, 4T1
Oh et al. 3, 5-Dicaffeoyl-Epi-Quinic acid isolated from edible halophyte Atriplex gmelinii inhibits adipogenesis via AMPK/MAPK pathway in 3T3-L1 adipocytes
BR112017007066A2 (pt) composições e métodos para melhorar a mobilidade ou a atividade, ou tratar a debilidade
BR112020004935A2 (pt) Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular
Tu et al. Pterostilbene attenuates ischemic stroke by modulating miR-21-5p/PDCD4 axis in vivo and in vitro
BR112019000783A2 (pt) peptídeo eficaz na prevenção da doença causada por geminivírus, e método para usar o mesmo

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]